IP Library Granted Patent US 9,163,075
Granted Patent B2
US 9,163,075 · App. 14/027,542 · Granted Oct 20, 2015

Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide

Inventors: John Knopf (Carlisle, MA); Jasbir Seehra (Lexington, MA)
Assignee: Acceleron Pharma Inc.
C07K14/71A61K47/48415C07K14/575A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,163,075
App. No.
14/027,542
Granted
Oct 20, 2015
Kind
B2
Abstract

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

Claims (36)

1. An isolated polynucleotide comprising a first nucleic acid sequence that hybridizes to a second nucleic acid sequence that is complementary to the sequence of SEQ ID NO:14 in the presence of 6.0× sodium chloride/sodium citrate (SSC) at 45° C. followed by a wash of 0.2×SSC at 65° C., wherein the first nucleic acid sequence encodes an ActRIIa-Fc fusion polypeptide that has the N-terminal sequence ILGRSETQE (SEQ ID NO:11).

2. The isolated polynucleotide of claim 1 , wherein the nucleic acid sequence comprises a coding sequence for a polypeptide comprising the amino acid sequence of SEQ ID NO:7.

3. The isolated polynucleotide of claim 1 , wherein the polynucleotide comprises the nucleic acid sequence of SEQ ID NO:14.

4. A recombinant polynucleotide comprising a promoter sequence operably linked to the polynucleotide of claim 1 .

5. A cell comprising the recombinant polynucleotide of claim 4 .

6. The cell of claim 5 , wherein the cell is a mammalian cell.

7. The cell of claim 6 , wherein the cell is a Chinese Hamster Ovary (CHO) cell.

8. A vector comprising at least one regulatory sequence operably linked to the polynucleotide of claim 1 .

9. A cell comprising the vector of claim 8 .

10. The cell of claim 9 , wherein the cell is a mammalian cell.

11. The cell of claim 10 , wherein the cell is a CHO cell.

12. A method of making an ActRIIa-Fc fusion polypeptide, wherein the method comprises:

i) providing a cell comprising the polynucleotide of claim 1 ;

ii) culturing the cell under conditions suitable for expression of the ActRIIa-Fc fusion polypeptide encoded by the recombinant polynucleotide; and

iii) recovering the expressed ActRIIa-Fc fusion polypeptide.

13. The method of claim 12 , wherein the cell is a CHO cell.

14. The method of claim 12 , wherein the polynucleotide sequence comprises a coding sequence for a polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:7.

15. The method of claim 12 , wherein the polynucleotide sequence comprises a coding sequence for a polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:7.

16. The method of claim 12 , wherein the polynucleotide sequence comprises a coding sequence for a polypeptide comprising the amino acid sequence of SEQ ID NO:7.

17. The method of claim 12 , wherein the polynucleotide comprises the nucleic acid sequence of SEQ ID NO:14.

18. The method of claim 12 , wherein the encoded polypeptide binds to activin and/or GDF11.

19. The method of claim 18 , wherein the encoded polypeptide binds to activin A.

20. The method of claim 18 , wherein the encoded polypeptide binds to activin B.

21. The method of claim 18 , wherein the encoded polypeptide binds to GDF11.

22. The method of claim 18 , wherein the encoded polypeptide binds to activin and GDF11.

23. The method of claim 22 , wherein the encoded polypeptide binds to activin A.

24. The method of claim 22 , wherein the encoded polypeptide binds to activin B.

25. The isolated polynucleotide of claim 1 , wherein the polynucleotide sequence comprises a coding sequence for a polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:7.

26. The isolated polynucleotide of claim 1 , wherein the polynucleotide sequence comprises a coding sequence for a polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:7.

27. The isolated polynucleotide of claim 1 , wherein the encoded polypeptide binds to activin and/or GDF11.

28. The isolated polynucleotide of claim 27 , wherein the encoded polypeptide binds to activin A.

29. The isolated polynucleotide of claim 27 , wherein the encoded polypeptide binds to activin B.

30. The isolated polynucleotide of claim 27 , wherein the encoded polypeptide binds to GDF11.

31. The isolated polynucleotide of claim 27 , wherein the encoded polypeptide binds to activin and GDF11.

32. The isolated polynucleotide of claim 31 , wherein the encoded polypeptide binds to activin A.

33. The isolated polynucleotide of claim 31 , wherein the encoded polypeptide binds to activin B.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: KNOPF, JOHN; SEEHRA, JASBIR
To: ACCELERON PHARMA INC.
Reel/Frame 031771/0538 →
Continuity (7)
Continuation 13176718 · Jul 5, 2011
Continuation 12284862 · Sep 24, 2008
Continuation 11603485 · Nov 22, 2006
Provisional Application 60739462 · Nov 23, 2005
Provisional Application 60783322 · Mar 17, 2006
Provisional Application 60844855 · Sep 15, 2006
Related Publication 20140079700A1 · Mar 20, 2014